Amgen is ending development of one early-stage obesity treatment while raising its full-year sales outlook on existing product performance. Merck posted stronger-than-expected second-quarter results led by Keytruda and raised revenue guidance while lowering profit guidance due to deal-related charges. Available reporting draws from a narrow set of sources representing limited ideological range.